GlassScriptPhysician profile
Michael Steven Heller
NPI 1336141621
$211.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.09 | 2019 | |
| Janssen Biotech, INC. | $30.84 | 2019 | |
| Tesaro, INC. | $28.04 | 2019 | |
| Merck Sharp & Dohme LLC | $19.51 | 2019 | |
| Pfizer INC. | $15.30 | 2019 | |
| Gilead Sciences, INC. | $13.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.91 | 2019 | |
| Genzyme Corporation | $12.31 | 2019 | |
| Genentech USA, INC. | $11.95 | 2019 | |
| Celgene Corporation | $10.99 | 2019 | |
| Eisai INC. | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.